Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Growing
The company is in a growing phase, with the latest annual income totaling USD 168.72K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 348.06.
Overvalued
The company’s latest PE is -1.23, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.88M shares, decreasing 10.83% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 159.88K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.05.